nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—thyroid cancer	0.283	1	CtDrD
Sorafenib—RET—thyroid cancer	0.156	0.618	CbGaD
Sorafenib—BRAF—thyroid cancer	0.0965	0.382	CbGaD
Sorafenib—MKNK1—Vandetanib—thyroid cancer	0.0422	0.125	CbGbCtD
Sorafenib—FLT4—Vandetanib—thyroid cancer	0.0353	0.105	CbGbCtD
Sorafenib—FLT3—Vandetanib—thyroid cancer	0.0305	0.0904	CbGbCtD
Sorafenib—KDR—Vandetanib—thyroid cancer	0.0305	0.0904	CbGbCtD
Sorafenib—RET—Vandetanib—thyroid cancer	0.0305	0.0904	CbGbCtD
Sorafenib—EPHA6—Vandetanib—thyroid cancer	0.027	0.0799	CbGbCtD
Sorafenib—EPHB6—Vandetanib—thyroid cancer	0.027	0.0799	CbGbCtD
Sorafenib—STK10—Vandetanib—thyroid cancer	0.0242	0.0718	CbGbCtD
Sorafenib—MAP2K5—Vandetanib—thyroid cancer	0.022	0.0654	CbGbCtD
Sorafenib—PDGFRB—Vandetanib—thyroid cancer	0.022	0.0654	CbGbCtD
Sorafenib—MAP3K19—Vandetanib—thyroid cancer	0.0203	0.0601	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—thyroid cancer	0.0154	0.0457	CbGbCtD
Sorafenib—ABCG2—Vandetanib—thyroid cancer	0.004	0.0119	CbGbCtD
Sorafenib—RET—parathyroid gland—thyroid cancer	0.00165	0.0546	CbGeAlD
Sorafenib—ABCC2—Doxorubicin—thyroid cancer	0.00162	0.0048	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—thyroid cancer	0.00146	0.00434	CbGbCtD
Sorafenib—Regorafenib—RET—thyroid cancer	0.00143	0.618	CrCbGaD
Sorafenib—CYP2B6—Doxorubicin—thyroid cancer	0.00103	0.00305	CbGbCtD
Sorafenib—Regorafenib—BRAF—thyroid cancer	0.000881	0.382	CrCbGaD
Sorafenib—CYP3A4—Vandetanib—thyroid cancer	0.000864	0.00256	CbGbCtD
Sorafenib—MAPK15—thyroid gland—thyroid cancer	0.000709	0.0234	CbGeAlD
Sorafenib—CDKL2—head—thyroid cancer	0.000699	0.0231	CbGeAlD
Sorafenib—MAPK15—head—thyroid cancer	0.000629	0.0208	CbGeAlD
Sorafenib—ABCB1—Doxorubicin—thyroid cancer	0.000527	0.00156	CbGbCtD
Sorafenib—RET—neck—thyroid cancer	0.000501	0.0165	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—thyroid cancer	0.000497	0.00147	CbGbCtD
Sorafenib—FLT1—neck—thyroid cancer	0.000442	0.0146	CbGeAlD
Sorafenib—RAF1—neck—thyroid cancer	0.000439	0.0145	CbGeAlD
Sorafenib—MAPK11—thyroid gland—thyroid cancer	0.000421	0.0139	CbGeAlD
Sorafenib—CDK7—thyroid gland—thyroid cancer	0.000414	0.0137	CbGeAlD
Sorafenib—MAP3K7—saliva-secreting gland—thyroid cancer	0.000414	0.0137	CbGeAlD
Sorafenib—TAOK2—thyroid gland—thyroid cancer	0.000411	0.0135	CbGeAlD
Sorafenib—AURKC—thyroid gland—thyroid cancer	0.000407	0.0134	CbGeAlD
Sorafenib—MKNK2—saliva-secreting gland—thyroid cancer	0.000401	0.0132	CbGeAlD
Sorafenib—KDR—neck—thyroid cancer	0.000373	0.0123	CbGeAlD
Sorafenib—MAPK11—head—thyroid cancer	0.000373	0.0123	CbGeAlD
Sorafenib—CDK7—head—thyroid cancer	0.000367	0.0121	CbGeAlD
Sorafenib—RALBP1—saliva-secreting gland—thyroid cancer	0.000362	0.0119	CbGeAlD
Sorafenib—AURKC—head—thyroid cancer	0.000361	0.0119	CbGeAlD
Sorafenib—ZAK—thyroid gland—thyroid cancer	0.000358	0.0118	CbGeAlD
Sorafenib—HIPK3—thyroid gland—thyroid cancer	0.00035	0.0115	CbGeAlD
Sorafenib—FLT1—saliva-secreting gland—thyroid cancer	0.000344	0.0114	CbGeAlD
Sorafenib—RAF1—saliva-secreting gland—thyroid cancer	0.000342	0.0113	CbGeAlD
Sorafenib—EPHB6—saliva-secreting gland—thyroid cancer	0.00034	0.0112	CbGeAlD
Sorafenib—EPHA6—head—thyroid cancer	0.000335	0.011	CbGeAlD
Sorafenib—KIT—neck—thyroid cancer	0.000331	0.0109	CbGeAlD
Sorafenib—TIE1—thyroid gland—thyroid cancer	0.000327	0.0108	CbGeAlD
Sorafenib—PDGFRB—neck—thyroid cancer	0.000323	0.0107	CbGeAlD
Sorafenib—MAP3K7—trachea—thyroid cancer	0.000319	0.0105	CbGeAlD
Sorafenib—ZAK—head—thyroid cancer	0.000317	0.0105	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—thyroid cancer	0.000316	0.000937	CbGbCtD
Sorafenib—BRAF—thyroid gland—thyroid cancer	0.000314	0.0103	CbGeAlD
Sorafenib—MKNK2—trachea—thyroid cancer	0.000309	0.0102	CbGeAlD
Sorafenib—MAP3K19—head—thyroid cancer	0.000304	0.01	CbGeAlD
Sorafenib—EPHX2—thyroid gland—thyroid cancer	0.0003	0.00989	CbGeAlD
Sorafenib—KDR—saliva-secreting gland—thyroid cancer	0.000291	0.00961	CbGeAlD
Sorafenib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000291	0.00961	CbGeAlD
Sorafenib—TIE1—head—thyroid cancer	0.00029	0.00958	CbGeAlD
Sorafenib—RALBP1—trachea—thyroid cancer	0.000279	0.00922	CbGeAlD
Sorafenib—FLT4—thyroid gland—thyroid cancer	0.00027	0.00892	CbGeAlD
Sorafenib—FGFR1—thyroid gland—thyroid cancer	0.000267	0.0088	CbGeAlD
Sorafenib—FLT1—trachea—thyroid cancer	0.000266	0.00877	CbGeAlD
Sorafenib—RAF1—trachea—thyroid cancer	0.000264	0.00872	CbGeAlD
Sorafenib—EPHB6—trachea—thyroid cancer	0.000263	0.00867	CbGeAlD
Sorafenib—MAPK11—lymph node—thyroid cancer	0.000261	0.00862	CbGeAlD
Sorafenib—KIT—saliva-secreting gland—thyroid cancer	0.000258	0.00851	CbGeAlD
Sorafenib—CDK7—lymph node—thyroid cancer	0.000257	0.00848	CbGeAlD
Sorafenib—TAOK2—lymph node—thyroid cancer	0.000255	0.00842	CbGeAlD
Sorafenib—AURKC—lymph node—thyroid cancer	0.000253	0.00835	CbGeAlD
Sorafenib—MAP3K7—thyroid gland—thyroid cancer	0.000252	0.00833	CbGeAlD
Sorafenib—PDGFRB—saliva-secreting gland—thyroid cancer	0.000252	0.00832	CbGeAlD
Sorafenib—PDGFRA—trachea—thyroid cancer	0.000249	0.00821	CbGeAlD
Sorafenib—MKNK2—thyroid gland—thyroid cancer	0.000245	0.00807	CbGeAlD
Sorafenib—MKNK1—thyroid gland—thyroid cancer	0.000242	0.00797	CbGeAlD
Sorafenib—FLT4—head—thyroid cancer	0.00024	0.00791	CbGeAlD
Sorafenib—RET—thyroid gland—thyroid cancer	0.000239	0.00787	CbGeAlD
Sorafenib—MAP2K5—trachea—thyroid cancer	0.000225	0.00741	CbGeAlD
Sorafenib—KDR—trachea—thyroid cancer	0.000225	0.00741	CbGeAlD
Sorafenib—ZAK—lymph node—thyroid cancer	0.000222	0.00733	CbGeAlD
Sorafenib—RALBP1—thyroid gland—thyroid cancer	0.000221	0.00729	CbGeAlD
Sorafenib—CSF1R—trachea—thyroid cancer	0.000219	0.00723	CbGeAlD
Sorafenib—HIPK3—lymph node—thyroid cancer	0.000217	0.00717	CbGeAlD
Sorafenib—MKNK2—head—thyroid cancer	0.000217	0.00716	CbGeAlD
Sorafenib—CDK7—Daunorubicin—Epirubicin—thyroid cancer	0.000215	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—thyroid cancer	0.000215	0.173	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—thyroid cancer	0.000215	0.173	CbGdCrCtD
Sorafenib—MKNK1—head—thyroid cancer	0.000214	0.00707	CbGeAlD
Sorafenib—RET—head—thyroid cancer	0.000212	0.00699	CbGeAlD
Sorafenib—FLT1—thyroid gland—thyroid cancer	0.00021	0.00694	CbGeAlD
Sorafenib—RAF1—thyroid gland—thyroid cancer	0.000209	0.00689	CbGeAlD
Sorafenib—EPHB6—thyroid gland—thyroid cancer	0.000208	0.00686	CbGeAlD
Sorafenib—TIE1—lymph node—thyroid cancer	0.000203	0.00671	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—thyroid cancer	0.000199	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—thyroid cancer	0.000199	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—thyroid cancer	0.000199	0.16	CbGdCrCtD
Sorafenib—KIT—trachea—thyroid cancer	0.000199	0.00657	CbGeAlD
Sorafenib—STK10—thyroid gland—thyroid cancer	0.000199	0.00656	CbGeAlD
Sorafenib—PDGFRA—thyroid gland—thyroid cancer	0.000197	0.0065	CbGeAlD
Sorafenib—RALBP1—head—thyroid cancer	0.000196	0.00647	CbGeAlD
Sorafenib—BRAF—lymph node—thyroid cancer	0.000195	0.00643	CbGeAlD
Sorafenib—PDGFRB—trachea—thyroid cancer	0.000194	0.00641	CbGeAlD
Sorafenib—FLT1—head—thyroid cancer	0.000186	0.00615	CbGeAlD
Sorafenib—EPHX2—lymph node—thyroid cancer	0.000186	0.00614	CbGeAlD
Sorafenib—RAF1—head—thyroid cancer	0.000185	0.00612	CbGeAlD
Sorafenib—FLT3—lymph node—thyroid cancer	0.000185	0.0061	CbGeAlD
Sorafenib—EPHB6—head—thyroid cancer	0.000184	0.00608	CbGeAlD
Sorafenib—KDR—thyroid gland—thyroid cancer	0.000178	0.00586	CbGeAlD
Sorafenib—MAP2K5—thyroid gland—thyroid cancer	0.000178	0.00586	CbGeAlD
Sorafenib—STK10—head—thyroid cancer	0.000177	0.00582	CbGeAlD
Sorafenib—PDGFRA—head—thyroid cancer	0.000175	0.00577	CbGeAlD
Sorafenib—Alopecia—Vandetanib—thyroid cancer	0.000174	0.00423	CcSEcCtD
Sorafenib—CSF1R—thyroid gland—thyroid cancer	0.000173	0.00572	CbGeAlD
Sorafenib—Mental disorder—Vandetanib—thyroid cancer	0.000172	0.00419	CcSEcCtD
Sorafenib—Malnutrition—Vandetanib—thyroid cancer	0.000171	0.00417	CcSEcCtD
Sorafenib—Hypophosphataemia—Epirubicin—thyroid cancer	0.000168	0.00409	CcSEcCtD
Sorafenib—FLT4—lymph node—thyroid cancer	0.000168	0.00554	CbGeAlD
Sorafenib—Dysgeusia—Vandetanib—thyroid cancer	0.000168	0.00408	CcSEcCtD
Sorafenib—FGFR1—lymph node—thyroid cancer	0.000166	0.00547	CbGeAlD
Sorafenib—Muscle spasms—Vandetanib—thyroid cancer	0.000165	0.00401	CcSEcCtD
Sorafenib—Mucosal inflammation—Doxorubicin—thyroid cancer	0.000163	0.00397	CcSEcCtD
Sorafenib—MAP2K5—head—thyroid cancer	0.000158	0.0052	CbGeAlD
Sorafenib—KDR—head—thyroid cancer	0.000158	0.0052	CbGeAlD
Sorafenib—KIT—thyroid gland—thyroid cancer	0.000157	0.0052	CbGeAlD
Sorafenib—MAP3K7—lymph node—thyroid cancer	0.000157	0.00517	CbGeAlD
Sorafenib—Hypophosphataemia—Doxorubicin—thyroid cancer	0.000155	0.00378	CcSEcCtD
Sorafenib—Folliculitis—Epirubicin—thyroid cancer	0.000155	0.00378	CcSEcCtD
Sorafenib—CSF1R—head—thyroid cancer	0.000154	0.00508	CbGeAlD
Sorafenib—PDGFRB—thyroid gland—thyroid cancer	0.000154	0.00507	CbGeAlD
Sorafenib—Embolism—Epirubicin—thyroid cancer	0.000152	0.0037	CcSEcCtD
Sorafenib—MKNK2—lymph node—thyroid cancer	0.000152	0.00502	CbGeAlD
Sorafenib—Loss of consciousness—Vandetanib—thyroid cancer	0.00015	0.00366	CcSEcCtD
Sorafenib—MKNK1—lymph node—thyroid cancer	0.00015	0.00495	CbGeAlD
Sorafenib—Cough—Vandetanib—thyroid cancer	0.000149	0.00364	CcSEcCtD
Sorafenib—RET—lymph node—thyroid cancer	0.000148	0.00489	CbGeAlD
Sorafenib—Hypertension—Vandetanib—thyroid cancer	0.000148	0.0036	CcSEcCtD
Sorafenib—Arthralgia—Vandetanib—thyroid cancer	0.000146	0.00355	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000145	0.00352	CcSEcCtD
Sorafenib—Folliculitis—Doxorubicin—thyroid cancer	0.000144	0.0035	CcSEcCtD
Sorafenib—Dry mouth—Vandetanib—thyroid cancer	0.000143	0.00347	CcSEcCtD
Sorafenib—ABCG2—saliva-secreting gland—thyroid cancer	0.000142	0.00467	CbGeAlD
Sorafenib—Embolism—Doxorubicin—thyroid cancer	0.000141	0.00342	CcSEcCtD
Sorafenib—KIT—head—thyroid cancer	0.00014	0.00461	CbGeAlD
Sorafenib—Infection—Vandetanib—thyroid cancer	0.000139	0.00338	CcSEcCtD
Sorafenib—RALBP1—lymph node—thyroid cancer	0.000137	0.00453	CbGeAlD
Sorafenib—Nervous system disorder—Vandetanib—thyroid cancer	0.000137	0.00333	CcSEcCtD
Sorafenib—Thrombocytopenia—Vandetanib—thyroid cancer	0.000137	0.00333	CcSEcCtD
Sorafenib—PDGFRB—head—thyroid cancer	0.000136	0.0045	CbGeAlD
Sorafenib—Skin disorder—Vandetanib—thyroid cancer	0.000136	0.0033	CcSEcCtD
Sorafenib—FLT1—lymph node—thyroid cancer	0.000131	0.00431	CbGeAlD
Sorafenib—RAF1—lymph node—thyroid cancer	0.00013	0.00428	CbGeAlD
Sorafenib—EPHB6—lymph node—thyroid cancer	0.000129	0.00426	CbGeAlD
Sorafenib—Pleural effusion—Epirubicin—thyroid cancer	0.000127	0.0031	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000127	0.0031	CcSEcCtD
Sorafenib—Dyspnoea—Vandetanib—thyroid cancer	0.000125	0.00303	CcSEcCtD
Sorafenib—STK10—lymph node—thyroid cancer	0.000124	0.00408	CbGeAlD
Sorafenib—Dyspepsia—Vandetanib—thyroid cancer	0.000123	0.00299	CcSEcCtD
Sorafenib—ABCC4—thyroid gland—thyroid cancer	0.000122	0.00404	CbGeAlD
Sorafenib—PDGFRA—lymph node—thyroid cancer	0.000122	0.00404	CbGeAlD
Sorafenib—HTR2B—thyroid gland—thyroid cancer	0.000122	0.00402	CbGeAlD
Sorafenib—Decreased appetite—Vandetanib—thyroid cancer	0.000121	0.00296	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000121	0.00294	CcSEcCtD
Sorafenib—Fatigue—Vandetanib—thyroid cancer	0.00012	0.00293	CcSEcCtD
Sorafenib—Pain—Vandetanib—thyroid cancer	0.000119	0.00291	CcSEcCtD
Sorafenib—Constipation—Vandetanib—thyroid cancer	0.000119	0.00291	CcSEcCtD
Sorafenib—Dysphonia—Epirubicin—thyroid cancer	0.000119	0.00289	CcSEcCtD
Sorafenib—Pleural effusion—Doxorubicin—thyroid cancer	0.000118	0.00287	CcSEcCtD
Sorafenib—HTR2C—head—thyroid cancer	0.000115	0.0038	CbGeAlD
Sorafenib—Neoplasm malignant—Epirubicin—thyroid cancer	0.000114	0.00278	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000114	0.00278	CcSEcCtD
Sorafenib—Abdominal pain—Vandetanib—thyroid cancer	0.00011	0.00269	CcSEcCtD
Sorafenib—Body temperature increased—Vandetanib—thyroid cancer	0.00011	0.00269	CcSEcCtD
Sorafenib—MAP2K5—lymph node—thyroid cancer	0.00011	0.00364	CbGeAlD
Sorafenib—KDR—lymph node—thyroid cancer	0.00011	0.00364	CbGeAlD
Sorafenib—Dysphonia—Doxorubicin—thyroid cancer	0.00011	0.00267	CcSEcCtD
Sorafenib—ABCC4—head—thyroid cancer	0.000109	0.00358	CbGeAlD
Sorafenib—HTR2B—head—thyroid cancer	0.000108	0.00357	CbGeAlD
Sorafenib—Bone disorder—Epirubicin—thyroid cancer	0.000108	0.00263	CcSEcCtD
Sorafenib—CSF1R—lymph node—thyroid cancer	0.000108	0.00355	CbGeAlD
Sorafenib—Hypocalcaemia—Epirubicin—thyroid cancer	0.000107	0.0026	CcSEcCtD
Sorafenib—Glossitis—Epirubicin—thyroid cancer	0.000106	0.00258	CcSEcCtD
Sorafenib—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000106	0.00257	CcSEcCtD
Sorafenib—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000103	0.00251	CcSEcCtD
Sorafenib—Asthenia—Vandetanib—thyroid cancer	0.0001	0.00244	CcSEcCtD
Sorafenib—Bone disorder—Doxorubicin—thyroid cancer	0.0001	0.00243	CcSEcCtD
Sorafenib—Pruritus—Vandetanib—thyroid cancer	9.88e-05	0.00241	CcSEcCtD
Sorafenib—Hypocalcaemia—Doxorubicin—thyroid cancer	9.86e-05	0.0024	CcSEcCtD
Sorafenib—Glossitis—Doxorubicin—thyroid cancer	9.8e-05	0.00239	CcSEcCtD
Sorafenib—KIT—lymph node—thyroid cancer	9.78e-05	0.00323	CbGeAlD
Sorafenib—Diarrhoea—Vandetanib—thyroid cancer	9.56e-05	0.00233	CcSEcCtD
Sorafenib—PDGFRB—lymph node—thyroid cancer	9.55e-05	0.00315	CbGeAlD
Sorafenib—Blood bilirubin increased—Doxorubicin—thyroid cancer	9.55e-05	0.00232	CcSEcCtD
Sorafenib—Influenza like illness—Epirubicin—thyroid cancer	9.48e-05	0.00231	CcSEcCtD
Sorafenib—Skin exfoliation—Epirubicin—thyroid cancer	9.32e-05	0.00227	CcSEcCtD
Sorafenib—Dizziness—Vandetanib—thyroid cancer	9.24e-05	0.00225	CcSEcCtD
Sorafenib—Neuropathy—Epirubicin—thyroid cancer	9.16e-05	0.00223	CcSEcCtD
Sorafenib—Vomiting—Vandetanib—thyroid cancer	8.88e-05	0.00216	CcSEcCtD
Sorafenib—Mouth ulceration—Epirubicin—thyroid cancer	8.82e-05	0.00215	CcSEcCtD
Sorafenib—Neoplasm—Epirubicin—thyroid cancer	8.82e-05	0.00215	CcSEcCtD
Sorafenib—Rash—Vandetanib—thyroid cancer	8.81e-05	0.00214	CcSEcCtD
Sorafenib—Dermatitis—Vandetanib—thyroid cancer	8.8e-05	0.00214	CcSEcCtD
Sorafenib—Influenza like illness—Doxorubicin—thyroid cancer	8.77e-05	0.00213	CcSEcCtD
Sorafenib—Headache—Vandetanib—thyroid cancer	8.75e-05	0.00213	CcSEcCtD
Sorafenib—ABCG2—thyroid gland—thyroid cancer	8.64e-05	0.00285	CbGeAlD
Sorafenib—Skin exfoliation—Doxorubicin—thyroid cancer	8.62e-05	0.0021	CcSEcCtD
Sorafenib—Neuropathy—Doxorubicin—thyroid cancer	8.48e-05	0.00206	CcSEcCtD
Sorafenib—CYP1A2—thyroid gland—thyroid cancer	8.32e-05	0.00274	CbGeAlD
Sorafenib—Nausea—Vandetanib—thyroid cancer	8.3e-05	0.00202	CcSEcCtD
Sorafenib—Neoplasm—Doxorubicin—thyroid cancer	8.17e-05	0.00199	CcSEcCtD
Sorafenib—Mouth ulceration—Doxorubicin—thyroid cancer	8.17e-05	0.00199	CcSEcCtD
Sorafenib—Hepatic function abnormal—Epirubicin—thyroid cancer	8.11e-05	0.00197	CcSEcCtD
Sorafenib—Hepatic failure—Epirubicin—thyroid cancer	7.88e-05	0.00192	CcSEcCtD
Sorafenib—Eczema—Epirubicin—thyroid cancer	7.88e-05	0.00192	CcSEcCtD
Sorafenib—Cardiac failure congestive—Epirubicin—thyroid cancer	7.81e-05	0.0019	CcSEcCtD
Sorafenib—Renal failure acute—Epirubicin—thyroid cancer	7.67e-05	0.00187	CcSEcCtD
Sorafenib—ABCC4—lymph node—thyroid cancer	7.61e-05	0.00251	CbGeAlD
Sorafenib—HTR2B—lymph node—thyroid cancer	7.57e-05	0.0025	CbGeAlD
Sorafenib—Dermatitis exfoliative—Epirubicin—thyroid cancer	7.51e-05	0.00183	CcSEcCtD
Sorafenib—Hepatic function abnormal—Doxorubicin—thyroid cancer	7.5e-05	0.00183	CcSEcCtD
Sorafenib—ABCC2—lymph node—thyroid cancer	7.36e-05	0.00243	CbGeAlD
Sorafenib—Hepatic failure—Doxorubicin—thyroid cancer	7.29e-05	0.00178	CcSEcCtD
Sorafenib—Eczema—Doxorubicin—thyroid cancer	7.29e-05	0.00178	CcSEcCtD
Sorafenib—Cardiac failure—Epirubicin—thyroid cancer	7.26e-05	0.00177	CcSEcCtD
Sorafenib—Cardiac failure congestive—Doxorubicin—thyroid cancer	7.23e-05	0.00176	CcSEcCtD
Sorafenib—Hyponatraemia—Epirubicin—thyroid cancer	7.11e-05	0.00173	CcSEcCtD
Sorafenib—Renal failure acute—Doxorubicin—thyroid cancer	7.1e-05	0.00173	CcSEcCtD
Sorafenib—Pain in extremity—Epirubicin—thyroid cancer	7.09e-05	0.00172	CcSEcCtD
Sorafenib—CYP2B6—head—thyroid cancer	7.07e-05	0.00233	CbGeAlD
Sorafenib—Dermatitis exfoliative—Doxorubicin—thyroid cancer	6.95e-05	0.00169	CcSEcCtD
Sorafenib—Cardiac failure—Doxorubicin—thyroid cancer	6.72e-05	0.00164	CcSEcCtD
Sorafenib—Mood swings—Epirubicin—thyroid cancer	6.71e-05	0.00163	CcSEcCtD
Sorafenib—Dehydration—Epirubicin—thyroid cancer	6.59e-05	0.0016	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—thyroid cancer	6.58e-05	0.0016	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—thyroid cancer	6.56e-05	0.0016	CcSEcCtD
Sorafenib—Dry skin—Epirubicin—thyroid cancer	6.49e-05	0.00158	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—thyroid cancer	6.47e-05	0.00158	CcSEcCtD
Sorafenib—Hypokalaemia—Epirubicin—thyroid cancer	6.45e-05	0.00157	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—thyroid cancer	6.4e-05	0.00156	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	6.38e-05	0.00155	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	6.38e-05	0.00155	CcSEcCtD
Sorafenib—Nasopharyngitis—Epirubicin—thyroid cancer	6.34e-05	0.00154	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—thyroid cancer	6.27e-05	0.00153	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	6.25e-05	0.00152	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—thyroid cancer	6.21e-05	0.00151	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—thyroid cancer	6.12e-05	0.00149	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—thyroid cancer	6.1e-05	0.00148	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—thyroid cancer	6.01e-05	0.00146	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—thyroid cancer	6e-05	0.00146	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—thyroid cancer	5.99e-05	0.00146	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—thyroid cancer	5.97e-05	0.00145	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—thyroid cancer	5.92e-05	0.00144	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	5.9e-05	0.00144	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	5.9e-05	0.00144	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—thyroid cancer	5.86e-05	0.00143	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—thyroid cancer	5.8e-05	0.00141	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	5.78e-05	0.00141	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—thyroid cancer	5.73e-05	0.00139	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—thyroid cancer	5.67e-05	0.00138	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—thyroid cancer	5.56e-05	0.00135	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—thyroid cancer	5.54e-05	0.00135	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—thyroid cancer	5.49e-05	0.00134	CcSEcCtD
Sorafenib—Infestation—Epirubicin—thyroid cancer	5.46e-05	0.00133	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—thyroid cancer	5.46e-05	0.00133	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	5.41e-05	0.00132	CcSEcCtD
Sorafenib—ABCB1—trachea—thyroid cancer	5.39e-05	0.00178	CbGeAlD
Sorafenib—ABCG2—lymph node—thyroid cancer	5.37e-05	0.00177	CbGeAlD
Sorafenib—Renal failure—Epirubicin—thyroid cancer	5.37e-05	0.00131	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—thyroid cancer	5.35e-05	0.0013	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—thyroid cancer	5.32e-05	0.0013	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—thyroid cancer	5.32e-05	0.0013	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—thyroid cancer	5.3e-05	0.00129	CcSEcCtD
Sorafenib—CYP2D6—head—thyroid cancer	5.26e-05	0.00173	CbGeAlD
Sorafenib—Hepatobiliary disease—Epirubicin—thyroid cancer	5.16e-05	0.00126	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—thyroid cancer	5.15e-05	0.00125	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—thyroid cancer	5.13e-05	0.00125	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—thyroid cancer	5.08e-05	0.00124	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—thyroid cancer	5.05e-05	0.00123	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—thyroid cancer	5.05e-05	0.00123	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	5.01e-05	0.00122	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—thyroid cancer	4.97e-05	0.00121	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—thyroid cancer	4.95e-05	0.00121	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—thyroid cancer	4.93e-05	0.0012	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—thyroid cancer	4.92e-05	0.0012	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—thyroid cancer	4.92e-05	0.0012	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—thyroid cancer	4.9e-05	0.00119	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—thyroid cancer	4.84e-05	0.00118	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—thyroid cancer	4.82e-05	0.00117	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—thyroid cancer	4.8e-05	0.00117	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—thyroid cancer	4.78e-05	0.00116	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—thyroid cancer	4.77e-05	0.00116	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—thyroid cancer	4.63e-05	0.00113	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—thyroid cancer	4.57e-05	0.00111	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—thyroid cancer	4.56e-05	0.00111	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—thyroid cancer	4.55e-05	0.00111	CcSEcCtD
Sorafenib—Flushing—Epirubicin—thyroid cancer	4.55e-05	0.00111	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—thyroid cancer	4.54e-05	0.0011	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—thyroid cancer	4.48e-05	0.00109	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—thyroid cancer	4.46e-05	0.00108	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—thyroid cancer	4.45e-05	0.00108	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—thyroid cancer	4.45e-05	0.00108	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—thyroid cancer	4.43e-05	0.00108	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—thyroid cancer	4.42e-05	0.00108	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—thyroid cancer	4.38e-05	0.00107	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—thyroid cancer	4.33e-05	0.00105	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—thyroid cancer	4.29e-05	0.00105	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—thyroid cancer	4.29e-05	0.00104	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—thyroid cancer	4.27e-05	0.00104	CcSEcCtD
Sorafenib—Erythema—Epirubicin—thyroid cancer	4.27e-05	0.00104	CcSEcCtD
Sorafenib—ABCB1—thyroid gland—thyroid cancer	4.26e-05	0.00141	CbGeAlD
Sorafenib—Tinnitus—Doxorubicin—thyroid cancer	4.23e-05	0.00103	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—thyroid cancer	4.21e-05	0.00102	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—thyroid cancer	4.21e-05	0.00102	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—thyroid cancer	4.18e-05	0.00102	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—thyroid cancer	4.11e-05	0.001	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—thyroid cancer	4.1e-05	0.000999	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—thyroid cancer	4.1e-05	0.000997	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—thyroid cancer	4.09e-05	0.000995	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—thyroid cancer	4.05e-05	0.000986	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—thyroid cancer	4.01e-05	0.000976	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—thyroid cancer	3.97e-05	0.000967	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—thyroid cancer	3.95e-05	0.000961	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—thyroid cancer	3.95e-05	0.000961	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—thyroid cancer	3.94e-05	0.00096	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—thyroid cancer	3.87e-05	0.000941	CcSEcCtD
Sorafenib—Syncope—Epirubicin—thyroid cancer	3.83e-05	0.000931	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—thyroid cancer	3.82e-05	0.00093	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—thyroid cancer	3.8e-05	0.000924	CcSEcCtD
Sorafenib—ABCB1—head—thyroid cancer	3.78e-05	0.00125	CbGeAlD
Sorafenib—Loss of consciousness—Epirubicin—thyroid cancer	3.75e-05	0.000913	CcSEcCtD
Sorafenib—Cough—Epirubicin—thyroid cancer	3.72e-05	0.000906	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—thyroid cancer	3.68e-05	0.000897	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—thyroid cancer	3.65e-05	0.000888	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—thyroid cancer	3.63e-05	0.000884	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—thyroid cancer	3.63e-05	0.000884	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	3.61e-05	0.000878	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—thyroid cancer	3.55e-05	0.000865	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—thyroid cancer	3.54e-05	0.000862	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—thyroid cancer	3.53e-05	0.00086	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—thyroid cancer	3.48e-05	0.000848	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—thyroid cancer	3.47e-05	0.000845	CcSEcCtD
Sorafenib—Infection—Epirubicin—thyroid cancer	3.46e-05	0.000842	CcSEcCtD
Sorafenib—Cough—Doxorubicin—thyroid cancer	3.45e-05	0.000839	CcSEcCtD
Sorafenib—Shock—Epirubicin—thyroid cancer	3.43e-05	0.000834	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—thyroid cancer	3.41e-05	0.000831	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—thyroid cancer	3.41e-05	0.00083	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—thyroid cancer	3.41e-05	0.00083	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—thyroid cancer	3.38e-05	0.000823	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—thyroid cancer	3.36e-05	0.000818	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—thyroid cancer	3.36e-05	0.000818	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	3.34e-05	0.000813	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—thyroid cancer	3.32e-05	0.000808	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—thyroid cancer	3.29e-05	0.0008	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—thyroid cancer	3.22e-05	0.000784	CcSEcCtD
Sorafenib—Infection—Doxorubicin—thyroid cancer	3.2e-05	0.000779	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.17e-05	0.000772	CcSEcCtD
Sorafenib—Shock—Doxorubicin—thyroid cancer	3.17e-05	0.000772	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—thyroid cancer	3.16e-05	0.000769	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—thyroid cancer	3.15e-05	0.000768	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—thyroid cancer	3.13e-05	0.000762	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—thyroid cancer	3.1e-05	0.000756	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—thyroid cancer	3.07e-05	0.000748	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—thyroid cancer	3.07e-05	0.000746	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—thyroid cancer	3.03e-05	0.000737	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—thyroid cancer	3.01e-05	0.000732	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—thyroid cancer	3e-05	0.000731	CcSEcCtD
Sorafenib—Pain—Epirubicin—thyroid cancer	2.98e-05	0.000725	CcSEcCtD
Sorafenib—Constipation—Epirubicin—thyroid cancer	2.98e-05	0.000725	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	2.94e-05	0.000715	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—thyroid cancer	2.87e-05	0.000699	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—thyroid cancer	2.85e-05	0.000693	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—thyroid cancer	2.84e-05	0.00069	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—thyroid cancer	2.8e-05	0.000682	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	2.78e-05	0.000677	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—thyroid cancer	2.78e-05	0.000676	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—thyroid cancer	2.77e-05	0.000673	CcSEcCtD
Sorafenib—Pain—Doxorubicin—thyroid cancer	2.76e-05	0.000671	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—thyroid cancer	2.76e-05	0.000671	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—thyroid cancer	2.75e-05	0.00067	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—thyroid cancer	2.75e-05	0.00067	CcSEcCtD
Sorafenib—ABCB1—lymph node—thyroid cancer	2.65e-05	0.000874	CbGeAlD
Sorafenib—Gastrointestinal pain—Doxorubicin—thyroid cancer	2.63e-05	0.000641	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—thyroid cancer	2.57e-05	0.000625	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—thyroid cancer	2.56e-05	0.000623	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—thyroid cancer	2.55e-05	0.00062	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—thyroid cancer	2.55e-05	0.00062	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—thyroid cancer	2.5e-05	0.000608	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—thyroid cancer	2.46e-05	0.0006	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—thyroid cancer	2.38e-05	0.00058	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—thyroid cancer	2.37e-05	0.000578	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—thyroid cancer	2.31e-05	0.000563	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—thyroid cancer	2.3e-05	0.000561	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—thyroid cancer	2.28e-05	0.000555	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—thyroid cancer	2.21e-05	0.000539	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—thyroid cancer	2.2e-05	0.000537	CcSEcCtD
Sorafenib—Rash—Epirubicin—thyroid cancer	2.2e-05	0.000534	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—thyroid cancer	2.19e-05	0.000534	CcSEcCtD
Sorafenib—Headache—Epirubicin—thyroid cancer	2.18e-05	0.000531	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—thyroid cancer	2.13e-05	0.000519	CcSEcCtD
Sorafenib—Nausea—Epirubicin—thyroid cancer	2.07e-05	0.000504	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—thyroid cancer	2.05e-05	0.000499	CcSEcCtD
Sorafenib—Rash—Doxorubicin—thyroid cancer	2.03e-05	0.000495	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—thyroid cancer	2.03e-05	0.000494	CcSEcCtD
Sorafenib—Headache—Doxorubicin—thyroid cancer	2.02e-05	0.000491	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—thyroid cancer	1.91e-05	0.000466	CcSEcCtD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.79e-06	3.41e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	1.78e-06	3.4e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—thyroid cancer	1.78e-06	3.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PTEN—thyroid cancer	1.78e-06	3.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—thyroid cancer	1.77e-06	3.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—AKT1—thyroid cancer	1.77e-06	3.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KRAS—thyroid cancer	1.77e-06	3.38e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—RXRA—thyroid cancer	1.77e-06	3.36e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.77e-06	3.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRG1—thyroid cancer	1.76e-06	3.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—thyroid cancer	1.76e-06	3.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—thyroid cancer	1.76e-06	3.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AKT1—thyroid cancer	1.76e-06	3.35e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HIF1A—thyroid cancer	1.76e-06	3.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—AKT1—thyroid cancer	1.74e-06	3.32e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTEN—thyroid cancer	1.74e-06	3.31e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—thyroid cancer	1.72e-06	3.27e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.71e-06	3.25e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—thyroid cancer	1.7e-06	3.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—thyroid cancer	1.7e-06	3.25e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TPR—thyroid cancer	1.69e-06	3.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—AKT1—thyroid cancer	1.69e-06	3.22e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKT1—thyroid cancer	1.68e-06	3.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—thyroid cancer	1.68e-06	3.19e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKT1—thyroid cancer	1.67e-06	3.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.66e-06	3.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	1.65e-06	3.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTEN—thyroid cancer	1.64e-06	3.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—BRAF—thyroid cancer	1.63e-06	3.11e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—thyroid cancer	1.63e-06	3.1e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.63e-06	3.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—thyroid cancer	1.62e-06	3.09e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—thyroid cancer	1.62e-06	3.09e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—thyroid cancer	1.6e-06	3.05e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—thyroid cancer	1.6e-06	3.05e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.59e-06	3.03e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.59e-06	3.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—thyroid cancer	1.59e-06	3.02e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TERT—thyroid cancer	1.58e-06	3.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PTEN—thyroid cancer	1.58e-06	3.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—thyroid cancer	1.57e-06	2.98e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—thyroid cancer	1.56e-06	2.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—BRAF—thyroid cancer	1.56e-06	2.96e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—thyroid cancer	1.55e-06	2.95e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—thyroid cancer	1.55e-06	2.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—thyroid cancer	1.55e-06	2.95e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—thyroid cancer	1.54e-06	2.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—thyroid cancer	1.53e-06	2.92e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—RXRA—thyroid cancer	1.53e-06	2.91e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.52e-06	2.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—thyroid cancer	1.52e-06	2.89e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	1.52e-06	2.89e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—thyroid cancer	1.51e-06	2.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.51e-06	2.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—thyroid cancer	1.51e-06	2.87e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—thyroid cancer	1.5e-06	2.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—thyroid cancer	1.5e-06	2.87e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.5e-06	2.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTEN—thyroid cancer	1.49e-06	2.85e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.49e-06	2.83e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.48e-06	2.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTEN—thyroid cancer	1.48e-06	2.82e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—thyroid cancer	1.48e-06	2.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—thyroid cancer	1.46e-06	2.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTEN—thyroid cancer	1.46e-06	2.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—BRAF—thyroid cancer	1.45e-06	2.77e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.44e-06	2.75e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.44e-06	2.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	1.42e-06	2.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—thyroid cancer	1.41e-06	2.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—thyroid cancer	1.4e-06	2.67e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—thyroid cancer	1.4e-06	2.66e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—thyroid cancer	1.4e-06	2.66e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—thyroid cancer	1.4e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.39e-06	2.65e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—thyroid cancer	1.38e-06	2.63e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.37e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—RXRA—thyroid cancer	1.37e-06	2.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—thyroid cancer	1.36e-06	2.6e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—thyroid cancer	1.36e-06	2.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—thyroid cancer	1.36e-06	2.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—thyroid cancer	1.35e-06	2.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—thyroid cancer	1.35e-06	2.57e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	1.33e-06	2.54e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—thyroid cancer	1.33e-06	2.54e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—RXRA—thyroid cancer	1.33e-06	2.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—thyroid cancer	1.33e-06	2.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—thyroid cancer	1.33e-06	2.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—thyroid cancer	1.33e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.33e-06	2.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—thyroid cancer	1.32e-06	2.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—thyroid cancer	1.32e-06	2.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	1.32e-06	2.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—thyroid cancer	1.32e-06	2.51e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TPR—thyroid cancer	1.31e-06	2.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—thyroid cancer	1.3e-06	2.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—thyroid cancer	1.29e-06	2.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—thyroid cancer	1.29e-06	2.45e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.28e-06	2.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—thyroid cancer	1.28e-06	2.43e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	1.28e-06	2.43e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.27e-06	2.41e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—thyroid cancer	1.26e-06	2.4e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—thyroid cancer	1.26e-06	2.4e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—thyroid cancer	1.26e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—RXRA—thyroid cancer	1.26e-06	2.39e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—thyroid cancer	1.26e-06	2.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—BRAF—thyroid cancer	1.25e-06	2.39e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—RXRA—thyroid cancer	1.25e-06	2.37e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.22e-06	2.33e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—thyroid cancer	1.22e-06	2.32e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	1.22e-06	2.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—thyroid cancer	1.22e-06	2.32e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.21e-06	2.31e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.21e-06	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	1.21e-06	2.31e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—thyroid cancer	1.2e-06	2.29e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—thyroid cancer	1.2e-06	2.29e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—thyroid cancer	1.2e-06	2.29e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—thyroid cancer	1.2e-06	2.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—thyroid cancer	1.19e-06	2.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	1.19e-06	2.27e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—thyroid cancer	1.19e-06	2.26e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.19e-06	2.26e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—thyroid cancer	1.19e-06	2.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	1.16e-06	2.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—thyroid cancer	1.16e-06	2.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.15e-06	2.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	1.15e-06	2.19e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—thyroid cancer	1.15e-06	2.18e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—thyroid cancer	1.14e-06	2.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—thyroid cancer	1.14e-06	2.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—thyroid cancer	1.14e-06	2.17e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	1.14e-06	2.17e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—thyroid cancer	1.14e-06	2.16e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—thyroid cancer	1.14e-06	2.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—thyroid cancer	1.13e-06	2.16e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—thyroid cancer	1.13e-06	2.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—thyroid cancer	1.13e-06	2.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—thyroid cancer	1.12e-06	2.14e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—thyroid cancer	1.12e-06	2.12e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—thyroid cancer	1.11e-06	2.11e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—thyroid cancer	1.1e-06	2.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—thyroid cancer	1.07e-06	2.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	1.07e-06	2.04e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—thyroid cancer	1.07e-06	2.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—RXRA—thyroid cancer	1.06e-06	2.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—thyroid cancer	1.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—thyroid cancer	1.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—thyroid cancer	1.05e-06	2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—thyroid cancer	1.05e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.04e-06	1.97e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—thyroid cancer	1.03e-06	1.97e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—thyroid cancer	1.03e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—thyroid cancer	1.03e-06	1.97e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	1.03e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	1.02e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—thyroid cancer	1.02e-06	1.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—thyroid cancer	1.02e-06	1.95e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—thyroid cancer	1.02e-06	1.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—thyroid cancer	1.01e-06	1.92e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—thyroid cancer	1e-06	1.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—thyroid cancer	9.99e-07	1.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—thyroid cancer	9.82e-07	1.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	9.79e-07	1.86e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	9.78e-07	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—thyroid cancer	9.77e-07	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	9.76e-07	1.86e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—thyroid cancer	9.75e-07	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—thyroid cancer	9.66e-07	1.84e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—thyroid cancer	9.66e-07	1.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—thyroid cancer	9.54e-07	1.82e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	9.49e-07	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—thyroid cancer	9.45e-07	1.8e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—thyroid cancer	9.19e-07	1.75e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—thyroid cancer	9.19e-07	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—thyroid cancer	9.16e-07	1.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—thyroid cancer	9.13e-07	1.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—thyroid cancer	9.13e-07	1.74e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—thyroid cancer	8.98e-07	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—thyroid cancer	8.84e-07	1.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	8.82e-07	1.68e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—thyroid cancer	8.79e-07	1.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—thyroid cancer	8.79e-07	1.67e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—thyroid cancer	8.77e-07	1.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—thyroid cancer	8.72e-07	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	8.7e-07	1.66e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—thyroid cancer	8.62e-07	1.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	8.62e-07	1.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—thyroid cancer	8.61e-07	1.64e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—thyroid cancer	8.53e-07	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—thyroid cancer	8.43e-07	1.6e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—thyroid cancer	8.42e-07	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—thyroid cancer	8.41e-07	1.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—thyroid cancer	8.34e-07	1.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	8.32e-07	1.59e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RXRA—thyroid cancer	8.21e-07	1.56e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—thyroid cancer	7.93e-07	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—thyroid cancer	7.89e-07	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—thyroid cancer	7.86e-07	1.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—thyroid cancer	7.86e-07	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	7.84e-07	1.49e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—thyroid cancer	7.83e-07	1.49e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—thyroid cancer	7.76e-07	1.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—thyroid cancer	7.76e-07	1.48e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—thyroid cancer	7.65e-07	1.46e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—thyroid cancer	7.6e-07	1.45e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	7.5e-07	1.43e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—thyroid cancer	7.48e-07	1.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—thyroid cancer	7.37e-07	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	7.35e-07	1.4e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—thyroid cancer	7.25e-07	1.38e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—thyroid cancer	7.25e-07	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—thyroid cancer	7.15e-07	1.36e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—thyroid cancer	6.99e-07	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—thyroid cancer	6.79e-07	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—thyroid cancer	6.78e-07	1.29e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—thyroid cancer	6.72e-07	1.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—thyroid cancer	6.68e-07	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—thyroid cancer	6.63e-07	1.26e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—thyroid cancer	6.62e-07	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	6.62e-07	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—thyroid cancer	6.31e-07	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—thyroid cancer	6.24e-07	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.19e-07	1.18e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—thyroid cancer	6.16e-07	1.17e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—thyroid cancer	6.1e-07	1.16e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—thyroid cancer	6.03e-07	1.15e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—thyroid cancer	5.92e-07	1.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—thyroid cancer	5.9e-07	1.12e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—thyroid cancer	5.77e-07	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—thyroid cancer	5.77e-07	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—thyroid cancer	5.44e-07	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—thyroid cancer	5.39e-07	1.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.29e-07	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—thyroid cancer	5.19e-07	9.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—thyroid cancer	5.09e-07	9.7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—thyroid cancer	4.61e-07	8.78e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—thyroid cancer	4.51e-07	8.59e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—thyroid cancer	4.41e-07	8.4e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.08e-07	7.77e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—thyroid cancer	3.82e-07	7.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—thyroid cancer	3.56e-07	6.78e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—thyroid cancer	3.41e-07	6.49e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—thyroid cancer	3.33e-07	6.34e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—thyroid cancer	3.14e-07	5.97e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—thyroid cancer	3.11e-07	5.92e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—thyroid cancer	2.66e-07	5.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—thyroid cancer	2.05e-07	3.91e-06	CbGpPWpGaD
